Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | BRD1 | O95696 | 2/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016173 | 0.88 | BRD1 (0.41) | BTKSRCBRD1BRPF1BRPF3 | |
| SCHEMBL22016175 | 0.85 | AAK1 (0.38) | MAPTBTKSRCAAK1GABRA5 | |
| SCHEMBL24312103 | 0.78 | HASPIN (0.44) | MAPTGABRA5NAMPTDAOTOP2A | |
| SCHEMBL29856743 | 0.77 | MAPT (0.44) | MAPTNAMPTTOP2ACYP19A1KCNH2 | |
| SCHEMBL19737524 | 0.77 | DAO (0.59) | MAPTBRD1BRPF1BRPF3DAO | |
| SCHEMBL14327804 | 0.77 | MAPT (0.44) | MAPTNAMPTTOP2ACYP19A1KCNH2 | |
| SCHEMBL24312244 | 0.76 | MAPT (0.41) | MAPTBTKBRPF1AAK1GABRA5 | |
| SCHEMBL35211579 | 0.73 | KDM4E (0.48) | MAPTNAMPTDAOTOP2AHASPIN | |
| SCHEMBL17120948 | 0.71 | SRC (0.45) | BTKSRCBRD1BRPF1BRPF3 | |
| SCHEMBL10151406 | 0.71 | MAPT (0.47) | MAPTNAMPTTOP2ACYP19A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | MAPT 3224/4885BTK 132/4885SRC 384/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | MAPT 3196/4885BTK 86/4885SRC 498/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | MAPT 949/4885BTK 399/4885SRC 2006/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | MAPT 949/4885BTK 399/4885SRC 2006/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | MAPT 2929/4885BTK 93/4885SRC 611/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | MAPT 949/4885BTK 399/4885SRC 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.